zurück
Pembrolizumab (new indication: cervical cancer with PD-L1 expression with a CPS ≥ 1, in combination with or without bevacizumab)
Subject:
- Active Sustance: Pembrolizumab
- Name: Keytruda®
- Therapeutic area: Cervical cancer
- Pharmaceutical company: MSD Sharp & Dohme GmbH
Time table:
- Start: 01.08.2022
- Final decision by G-BA: 02.02.2023
Final decision:
- Adults for whom pembrolizumab is the first-line therapy:
a1. Pembrolizumab used in combination with cisplatin and paclitaxel or carboplatin and paclitaxel: Indication for a considerable additional benefit
a2. Pembrolizumab used in combination with any chemotherapy other than cisplatin and paclitaxel or carboplatin and paclitaxel:
No additional benefit proved
- Adults with first-line chemotherapy and for whom further antineoplastic therapy is being considered: No additional benefit proved